Intellia Therapeutics (NTLA) Tops Q4 EPS by 13c

Intellia Therapeutics (NASDAQ: NTLA) reported Q4 EPS of ($0.83), $0.13 better than the analyst estimate of ($0.96).

For earnings history and earnings-related data on Intellia Therapeutics (NTLA) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• Crusoe in talks to raise $3B in funding - Bloomberg
• Morgan Stanley Upgrades Galp Energia SGPS SA (GALP:LI) (GLPEF) to Overweight